Ryaltris

Medicinal product

(Invented) name

Ryaltris

Active substance (s)

Mometazono furoatas/Olopatadino hidrochloridas

Strength

25 µg/600 µg/spūsnyje

Pharmaceutical form

nosies purškalas (suspensija)

Route (s) of administration

įkvėpti

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

R01AD59, mometasone, combinations

Marketing authorisation holder

Glenmark Pharmaceuticals s.r.o., Čekija

Date of authorisation

2026-07-24

Date of renewal

Documents

6109_Ryaltris.docx

6109_pakuotes lapelis_2026-07-24.docx

Stage

Registruotas

Controlled?

No

Controlled substance type

Legal basis

10b

Procedure number

SE/H/2040/001/E/001

Marketing authorisation procedure

Kartotinė procedūra

Qualitative and quantitative composition

Iišpurškiamoje dozėje (pro purkštuką išsiskiriančioje dozėje) yra	1 dozėje
Mometazono furoatas	25 µg
Olopatadino hidrochloridas	600 µg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
121762	107871	1107871	buteliukas	56 spūsniai N1		Receptinis	LT/1/26/6109/001	Netiekiama	-	-	No	-	-
121763	107872	1107872	buteliukas	120 spūsnių N1		Receptinis	LT/1/26/6109/002	Netiekiama	-	-	No	-	-
121764	107873	1107873	buteliukas	240 spūsnių N1		Receptinis	LT/1/26/6109/003	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2026-07-24	Registruotas